Platelet receptor glycoprotein VI in thrombus formation and growth in atrial fibrillation and venous thromboembolism

Glycoprotein six Receptor in Atrial FIbrillation and ThromboEmbolism

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN33370579

Enrollment

150

Registered

2016-08-02

Start date

2016-10-01

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation and venous thromboembolism Circulatory System Atrial fibrillation and venous thromboembolism

Interventions

This study involves taking blood samples taken from patients for genetic analysis, platelet activation and glycoprotein VI dimer levels via flow cytometry. This will be carried out by laboratory testi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with a new diagnosis of AF and those with persistent or paroxysmal AF, whether they are on anticoagulation or not 2. Patients with confirmed venous thromboembolic disease 3. Admitted under a medical team to Cambridge University Hospitals

Exclusion criteria

Exclusion criteria: 1. No clear confirmation of the presence of atrial fibrillation in medical notes or ECG (for AF patients) 2. No confirmed venous thromboembolic disease on any imaging modality (only for those with suspected VTE) 3. Age less than 18 years 4. Pregnancy 5. Active and known malignancy 6. Known platelet disorder 7. Known HIV/AIDS 8. Known hepatitis B or hepatitis C infection 9. Admitted with a transient ischaemic attack or stroke – ischaemic or haemorrhagic 10.Patients who lack capacity

Design outcomes

Primary

Measure	Time frame
Measuring platelet glycoprotein VI dimer levels from blood taken when patients are admitted to hospital with atrial fibrillation or venous thromboembolism, as measured by mean fluorescence on flow cytometry	—

Secondary

Measure	Time frame
1. Measure the correlation between glycoprotein VI dimer mean florescence intensity on flow cytometry with levels of known common blood biomarkers for atrial fibrillation, coagulation and stroke (d-dimer, hs-CRP, BNP) 2. Measure the correlation between glycoprotein VI dimer levels as measured by mean fluorescence on flow cytometry and estimated risk of stroke as stratified by the CHADS2-VASC2 score calculated at the time of participant involvement 3. Determine the genetic basis for atrial fibrillation and venous thromboembolism and a therefore look for a genetic basis for possible pre-disposition to stroke	—

Measure

Time frame

1. Measure the correlation between glycoprotein VI dimer mean florescence intensity on flow cytometry with levels of known common blood biomarkers for atrial fibrillation, coagulation and stroke (d-dimer, hs-CRP, BNP) 2. Measure the correlation between glycoprotein VI dimer levels as measured by mean fluorescence on flow cytometry and estimated risk of stroke as stratified by the CHADS2-VASC2 score calculated at the time of participant involvement 3. Determine the genetic basis for atrial fibrillation and venous thromboembolism and a therefore look for a genetic basis for possible pre-disposition to stroke

—

Countries

England, United Kingdom

Contacts

Public ContactIsuru Induruwa

ii231@cam.ac.uk+44 1223 245151

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026